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Abstract
Introduction We aimed to integrate all available
epidemiological evidence to characterise an exposure–
response model of ambient fine particulate matter (PM2.5) and
the risk of chronic kidney disease (CKD) across the spectrum
of PM2.5 concentrations experienced by humans. We then
estimated the global and national burden of CKD attributable
to PM2.5.
Methods We collected data from prior studies on the
association of PM2.5 with CKD and used an integrative meta-
regression approach to build non-linear exposure–response
models of the risk of CKD associated with PM2.5 exposure.
We then estimated the 2017 global and national incidence,
prevalence, disability-adjusted life-years (DALYs) and
deaths due to CKD attributable to PM2.5 in 194 countries and
territories. Burden estimates were generated by linkage of
risk estimates to Global Burden of Disease study datasets.
Results The exposure–response function exhibited evidence
of an increase in risk with increasing PM2.5 concentrations,
where the rate of risk increase gradually attenuated at
higher PM2.5 concentrations. Globally, in 2017, there were
3 284 358.2 (95% UI 2 800 710.5 to 3 747 046.1) incident
and 122 409 460.2 (108 142 312.2 to 136 424 137.9)
prevalent cases of CKD attributable to PM2.5, and 6 593
134.6 (5 705 180.4 to 7 479 818.4) DALYs and 211 019.2
(184 292.5 to 236 520.4) deaths due to CKD attributable
to PM2.5. The burden was disproportionately borne by low
income and lower middle income countries and exhibited
substantial geographic variability, even among countries with
similar levels of sociodemographic development. Globally,
72.8% of prevalent cases of CKD attributable to PM2.5 and
74.2% of DALYs due to CKD attributable to PM2.5 were due
to concentrations above 10 µg/m3, the WHO air quality
guidelines.
Conclusion The global burden of CKD attributable to PM2.5
is substantial, varies by geography and is disproportionally
borne by disadvantaged countries. Most of the burden is
associated with PM2.5 levels above the WHO guidelines,
suggesting that achieving those targets may yield reduction
in CKD burden.
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Introduction
A number of large epidemiological studies
have described the relationship between

Key questions
What is already known?
►► Ambient fine particulate matter (PM2.5) is associated

with increased risk of chronic kidney disease (CKD).

What are the new findings?
►► The shape of the relationship between PM2.5 and

CKD suggests that increased PM2.5 concentrations
were associated with increased risk of CKD at lower
concentrations of PM2.5, and the rate of risk increase
attenuated at higher levels of PM2.5.
►► Globally, PM2.5 was associated with 3 284 358 incident cases of CKD each year.
►► The burden of CKD attributable to PM2.5 was disproportionately borne by low income and lower middle
income countries
►► Nearly 3/4 of the global burden of CKD attributable
to PM2.5 was associated with PM2.5 levels above the
WHO air quality guidelines

What do the new findings imply?
►► The global and national effort aimed at reducing bur-

den of non-communicable diseases in general and
kidney disease in particular should recognise fine
particulate matter air pollution as a driver of burden
of CKD globally.
►► Achieving the WHO targets for fine particulate matter
may yield substantial reduction in CKD burden.

ambient fine particulate matter of <2.5 µm in
aerodynamic diameter (PM2.5) and chronic
kidney disease (CKD).1–3 Several experimental studies in mice and rats suggest that
inhalation of PM2.5 promotes oxidative stress,
inflammation and DNA damage in kidney
tissue and leads to structural chronic kidney
injury manifested by glomerulosclerosis,
mesangial expansion, tubular atrophy and
vascular damage, providing a plausible biological mechanism for the injurious effect of
PM2.5 on the kidney.4–10 We recently described
global and national estimates of CKD burden
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Methods
Characterisation of the risk of CKD associated with PM2.5
To estimate the magnitude of the risk of CKD associated
with PM2.5 exposure across the spectrum of concentrations
experienced by humans, we curated all available evidence
for use in an integrative meta-regression approach. Prior
work in the quantification of the global health risk of
PM2.5 has, for diseases with limited evidence across the
entire PM2.5 exposure range, additionally incorporated
outcome associations with secondhand smoke, household
air pollution and active smoking exposures17 as a means
of calibration of exposure–response curve morphology
at higher—otherwise understudied—PM2.5 exposure
values. However, recent literature has suggested that this
approach may result in underestimation of risk,18 and
therefore may not be the most optimal strategy to characterise risk if a preponderance of studies is available.
Here, due to a potentially limited pool of PM2.5 and CKD
studies, we chose to estimate the non-linear exposure–
response with methodological considerations based on
both the integrated exposure–response (IER) method,
which incorporates proxy exposures into estimation, and
global exposure morality model (GEMM) method, which
relies exclusively on PM2.5 data, allowing for comparison
of results generated from data with and without inclusion
of proxy exposures.

Web of Science and the Cochrane library for literature
on cohort, case–control and cross-
sectional studies of
the association between CKD and PM2.5.20 21 Searches
were also conducted to identify studies on CKD and
secondhand smoke, household air pollution and active
smoking.17 Following the strategies outlined in our
protocol, searches on 20 May 2019 resulted in identifying
for potential inclusion 322 studies on ambient fine particulate matter air pollution, 301 on secondhand smoke
and 535 on active smoking. We screened these studies
based on the following inclusion criteria: published in
a peer-
reviewed journal; reported as having a cohort,
case–control or cross-sectional study design; provided a
measure of relative risk; available in English; and assessed
risk of a kidney disease outcome. We initially selected a
CKD outcome definition of an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, as this is the most
commonly used outcome definition in epidemiological
studies of CKD.22–36 However, this definition was relaxed
for proxy exposures, due to paucity of usable studies, to
include kidney disease outcomes that have displayed relative risks similar in magnitude to incident eGFR <60 mL/
min/1.73 m2 in prior literature, such as eGFR decline
≥30% from baseline or incident stage 4 CKD.2 We furthermore excluded abstracts, as they lacked sufficient detail
necessary for assessing risk of bias. Exposure type specific
inclusion criteria included requiring studies on secondhand smoke to have a never-smoker comparison group
and requiring studies on active smoking to have exposure definitions based on number cigarettes smoked per
day. From selected studies, data were abstracted on study
design, study outcome, range of exposure in the cohort,
relative risk, relative risk uncertainty and aspects needed
for risk of bias assessment. Studies risk of bias were scored
using the Newcastle-Ottawa Scales for cohort and case–
control studies and an adapted Newcastle–Ottawa scale
for cross-
sectional studies.37 38 These scales allow for
assignment of a numeric score to each study as a means of
assessing the potential of bias, where a higher score indicates less potential. Each study was independently scored
by two study team members; any discrepancies in score
were resolved by additional scoring by third member,
where the majority score was taken. Scoring components that were tailored specifically for this study have
been included in the protocol (supplement). Studies
that scored less than 50% of the maximum score were
considered to lack suitability for inclusion in the analyses.20 After applying eligibility criteria, we identified for
inclusion in analyses six studies on PM2.5 and CKD, one
study on secondhand smoke and CKD and three studies
on active smoking and CKD. Further details are provided
in the supplement.

Data curation
The protocol followed for identification of available
evidence for incorporation in integrative meta-regression
is reported following recommend guidelines (online
supplementary material).19 We searched PubMed,

Integrated non-linear exposure–response model
To incorporate all relevant evidence on the association
between PM2.5 and CKD, we constructed integrated non-
linear exposure–response models by adapting aspects of
the GEMM approach by Burnett et al (2018)18 and the
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attributable to PM2.5 pollution based on an exposure–
response function derived from a single US cohort with
a narrow range of PM2.5 exposure that may limit generalisability of these estimates.11 A significant knowledge gap
exists in that the PM2.5-CKD exposure–response function
across the concentrations of PM2.5 experienced by humans
worldwide has not been characterised.12–14 Characterisation of an exposure–response function that integrates all
available evidence will allow for more accurate estimation
of CKD burden for a geographic area or a population
group with well-defined exposure estimates. Estimation
of burden of kidney disease will also contribute to the
global discussion about the relationship between environmental air pollution and non-communicable diseases
in general and specifically on the contribution of air
pollution to the global and national burden of CKD.14–16
In this work, we systematically searched all published
reports on the relationship between PM2.5 and CKD and
used advanced methodologies to build and characterise
an integrated non-linear exposure response model; we
then generated estimates of the global and national
burden of CKD attributable to PM2.5 air pollution and
estimated the burden attributable to levels of PM2.5
exceeding the WHO PM2.5 air quality standards.

BMJ Global Health

Bowe B, et al. BMJ Global Health 2020;5:e002063. doi:10.1136/bmjgh-2019-002063

studies; and (D) additionally included data from proxy
exposure studies and did not deweight cross-sectional
studies. Data were weighted by sampling variance and
risk of bias using the quality effects weighting method as
proposed by Doi and Thalib.40 Models in cross-sectional
studies were deweighted by setting the risk of bias scores
to a minimal value (1), a reflection of their inability to
establish temporality in exposure–response relations
(and the resultant higher risk of bias). Random effects
models were fit using the 
rma.
mv routine in R with
the options: method=“REML”, optimizer=“optim”. A
compound symmetry (CS) covariance structure was specified; for models that incorporated proxy exposures, a
structure of (“CS”, “CS”), adding correlation at the study
(nested within exposure type) and exposure type levels,
was used.17 18 Two studies that were done in potentially
the same cohort by the same group (Chen and Yang)
were treated as being at the same study level. We additionally tested models specifying unstructured covariance;
however, results were robust to this change, so the more
parsimonious structure was kept.18 41 Resultant estimated
risk are plotted for each of the four model versions, where
a reference of 2.4 µg/m3 is used, and all risk under 2.4 µg/
m3 was set to null, a reflection of burden estimation where
a theoretical minimum risk exposure level (TMREL) of
2.4 µg/m3 was used.18 As a means of visual presentation of
fit for comparison of models with and without incorporation of proxy exposure data, we present for the best fit
models (among
the 150 models in the ensemble) a plot
)
(
of the log RRsi along with plots of the studies data points.
One thousand replications using a parametric bootstrap
approach was used in obtaining the UI, where the 2.5th
and 97.5th percentiles of the resultant distribution of the
ensemble estimates are reported.18 39
Burden estimation
Data on the global burden of CKD were obtained from
the 2017 Global Burden of Disease (GBD) study,42
where the GBD estimates CKD stage 1–5. Briefly, deaths
due to CKD are estimated using vital registration and
verbal autopsy data sources, to which a garbage coding
algorithm is applied in order to redistribute cause of
death codes deemed implausible or possibly miscoded.
Prevalence is estimated from a collation of studies
on population level CKD rates and is augmented by
population-
based surveys of renal function and renal
registry reports, including end-stage renal disease data
from 109 countries and data on CKD stage 3–5 from
59 countries.43 These data were linked with 2017 PM2.5
global exposure estimates made available by GBD
investigators44–47; GBD estimates population weighted
annual mean PM2.5 concentrations for each country
and territory at an approximate 11 km × 11 km resolution from a synthesis of satellite-based estimates, chemical transport models and ground-
level measurements
from 9960 monitors from 108 countries; the population-
weighted root mean squared error of the model was
8.11 µg/m3.48 Using risk estimates from the integrated
3
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IER approach by Burnett et al (2014).17 The GEMM uses
state-of-the-art modelling techniques to model the shape
of the association between PM2.5 and disease, leveraging
study data that span the PM2.5 exposure range experienced by humans. A series of random effects models
that pool the relative risk among studies are constructed,
each assuming a different monotonic functional form,
which are then ensembled to create a final estimate of
the exposure–response.
( ) The relative
(
( risk)for a(model
)) may
be equated by RR z = exp θlog 1 + αz ∗ ω z , where
RR(z) is the relative risk of z the exposure value, θ is the
parameter
( ) estimate1and ω(z) is a logistic weighting func( (
)) with r the range of pollutant
tion ω z =
1+exp − z−µ
τ
∗r


concentrations and α, μ and τ predefined parameters that
affect the shape and curvature of estimated relations. A
study’s log(RR) is then estimated as
(
)
{
(
zsi )
1
))
(
(
−
log (RRsi ) = θ ∗ log 1 + α ∗
z −µ
1+exp − siτ ∗r
(
(
)}
(
)
( 1(
))
log 1 + zαs0 ∗
1+exp − zsoτ−µ
∗r
	

where z is the exposure for study s, i versus 0 is the ith
exposure contrast, and hyperparameter values are set
as α = (1,3,5,7,9),  τ = (0.1, 0.2, 0.3, 0.4, 0.5, 0.6), and
μ = (0th, 25th, 50th, 75th and 100th percentile of the
PM2.5 distribution among all study cohorts). This results
in a total 150 curves with monotonic morphology that
linear, supralinear, sublinear and
include linear, log-
S shapes, where the choice of hyperparameters were
made in line with prior literature.18 These models were
used to construct an ensembled estimate (a weighted
average), where models are weighted by model fit (better
fit resulting in a higher weight), and errors are obtained
through bootstrap.39 In defining zsi and zs0 for PM2.5, if
risk across several categories of exposure were given, the
median of each category was used, otherwise the 5th and
95th percentile (assuming a normal distribution) were
used. Contrast values for secondhand smoke and active
smoking were based of prior literature, where moderate
or severe passive smoking and number of cigarettes per
day were translated into PM2.5 mass inhaled concentration; a zs0 of zero was used.17 For the distribution of μ, we
assumed an uniform distribution between the minimal
and maximal PM2.5 values across the studies, as this
allowed for a wide range of μ whose definition was not
dominated by any one study with a large sample.
We employed four strategies in building the integrated
non-
linear exposure response model where we: (A)
constructed the model using exclusively PM2.5 study data
and deweighted cross-sectional studies40 (this approach
most closely emulates the analytic considerations and
underlying assumptions of the GEMM model by Burnett
et al18); (B) constructed the model using PM2.5 study data
only and did not deweight cross-sectional studies; (c) additionally included data from the proxy exposure studies
based on IER methods17 and deweighted cross-sectional

BMJ Global Health

the population attributable
( fraction (PAF) based
) on the
g
TMREL
equation PAF = 1 − exp ∆v (z , z
where
) ∗ β̂
 )

( g TMREL
∆v z , z
is the difference in the transformed PM2.5
contrast between zg the population-weighted PM2.5 exposure estimate for the country or territory and zTMREL the
TMREL exposure level, and β  the parameter estimate.39
We set a TMREL of 2.4 µg/m3 and estimate the global
CKD burden attributable to PM2.5.18 We estimated the
absolute number, rate per 100 000 persons, and age-
standardised rate per 100 000 persons for CKD incidence,
prevalence, disability-
adjusted life-
years (DALYs) and
deaths attributable to PM2.5. Further details are provided
in the supplement. Ninety-
five percent uncertainty
intervals were obtained through 1000 realisations of the
burden, where uncertainty was contributed to by risk
estimation and uncertainty in GBD burden estimates. All
reported numbers should be interpreted along with their
95% uncertainty intervals.
We then estimated the burden of CKD due to PM2.5
for 194 countries and territories based on the risk estimates of the integrated non-linear exposure–response
model from the strategy of using only PM2.5 studies and
deweighting the cross-sectional studies; we choose this
strategy as our primary approach as it does not rely on
proxy exposures (known to result in underestimation
of risk), and—by deweighting cross-sectional studies—it
will more closely approximate the ideal setting in which
only high-quality longitudinal studies of PM2.5 and CKD
are used. We estimated burden by World Bank income
classification and conducted an estimated to expected
ratio analyses by constructing a negative binomial model
of the relation between age-standardised DALY rates of
CKD due to PM2.5 and sociodemographic index (SDI),
a summary measure of a country’s level of sociodemographic development,49 where SDI was treated as a
restricted cubic spline to allow for non-linearity in the
association. This ratio compares the estimated burden
of CKD attributable to PM2.5 to the expected burden of
CKD attributable to PM2.5 based on a country’s SDI. We
furthermore estimated the burden of CKD attributable
to PM2.5 concentrations above a TMREL (counterfactual)
of 10 µg/m3, the WHO air quality standard for average
annual PM2.5 concentrations. Estimates for global burden
and burden by World Bank income category were calculated through summation of the 194 countries and territories in our data. Maps were generated in ArcMap 10.5
(ESRI, Redlands, California, USA) and R Studio (R Core
Team) and plots in SAS EG V.7.1 (SAS Institute, Cary,
North Carolina, USA).
Patient and public involvement
No patients were involved in developing the hypothesis,
the specific aims, or the research questions, nor were
they involved in developing plans for design or implementation of the study. No patients were involved in the
interpretation or writing up of results. There are no plans
4

to disseminate the results of the research to study participants.
Results
An integrated non-linear exposure–response model
We integrated all available evidence to build and characterise a non-linear exposure–response model of the
relationship between PM2.5 and risk of CKD; a flow chart
of data curation and description of included studies are
available in supplementary figure S1 and table 1.1 2 50–57
For potential inclusion in the meta-regression analyses,
we identified six studies on PM2.5, one study on secondhand smoke, and three studies on active smoking (online
supplementary figure S1 and table 1), leading to a total
of 30 data points, 15 of which were from PM2.5 studies. No
studies on household air pollution and risk of CKD were
identified.
We considered four analytic approaches to building the
integrated non-linear exposure response function: (A)
in analyses considering only studies on PM2.5 and risk of
CKD and where cross-sectional studies were deweighted
(we designated this as the primary model), the exposure–
response function exhibited evidence of an increase in
risk with increasing PM2.5 concentrations and the rate
of risk increase gradually attenuated as PM2.5 concentration increased (figure 1A); (B) analyses considering
only studies on PM2.5 and CKD and where cross-sectional
studies were not deweighted produced consistent results
(figure 1B); (C) analyses that also included active and
passive smoking data as proxies of PM2.5 exposure and
where cross-sectional studies were deweighted yielded an
exposure–response function that exhibited less risk for
each given PM2.5 concentration than when proxy exposures were not included (figure 1C); (D) analyses that
also included active and passive smoking data as proxies
of PM2.5 exposure and where cross-sectional studies were
not deweighted yielded results consistent with those in
approach C(figure 1D). Plots of estimated risk versus
study data points suggested that compared with models
built using only PM2.5 data, incorporation of proxy exposures resulted in underestimation of risk associated with
PM2.5 exposure (online supplementary figures S2A–D).
Global Burden of CKD attributable to PM2.5 air pollution
We estimated the global burden of CKD attributable
to air pollution using the PM2.5 exposure–risk function
where only studies on PM2.5 and CKD were used and
cross-sectional studies were deweighted (we designated
this as the primary model and is depicted in figure 1A).
At the global level, our estimates suggest that incidence
of CKD attributable to PM2.5 air pollution was 3 284 358.2
(95% UI 2 800 710.5 to 3 747 046.1) and prevalence was
122 409 460.2 (108 142 312.2 to 136 424 137.9). There
were 6 593 134.6 (5 705 180.4 to 7 436 870.1) DALYs and
211 019.2 (184 292.5 to 236 520.4) deaths due to CKD
attributable to PM2.5 pollution. Rates per 100 000 and age-
standardised rates per 100 000 for incidence, prevalence,
Bowe B, et al. BMJ Global Health 2020;5:e002063. doi:10.1136/bmjgh-2019-002063
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non-
linear exposure–response models, we calculated
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Cohort

Case-
Control

Cohort

Jhee et al
(2018)*54

Ejerblad et al
(2004)*55

Hall et al
(2016)*56

5

Active
smoking

Active
smoking

Passive
smoking

PM2.5

PM2.5

PM2.5

PM2.5

PM2.5

PM2.5

Exposure
source

–

–

–

12.2 (0.6)

12.2 (6.1–16.8)

24.3 (12.8–48.2)

26.6 (5.0)

27.1 (5.8–49.6)

11.8 (5.0–22.1)

eGFR decline
≥30%

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

eGFR <60 mL/
min/1.73 m2

Mean or median
exposure range (SD
or IQR)
CKD definition

1.14 (1.09 to 1.20)

Quartile 4 versus 1

1.15 (1.05 to 1.26)
1.03 (0.97 to 1.09)

1.01 (0.96 to 1.06)

Quintile 5 versus 1
Every 5.67 µg/m3 increase

Every 4.1 µg/m3 increase

Age, sex, BMI, diabetes, hypertension, total cholesterol, education
level, physical activity, prevalent cardiovascular disease and alcohol
consumption.

Age, gender, education level, alcohol consumption, use of paracetamol
and salicylates, pipe smoking, cigar smoking and snuff use.

Age, sex, BMI, systolic BP, history of hypertension, history of diabetes,
alcohol status, education levels, income levels, marital status,
haemoglobin and serum albumin.

Age, sex, BMI, education level, neighbourhood socioeconomic
status, medical insurance, smoking status, physical activity, alcohol
consumption, occupation, hyperlipidaemia, use of non-steroidal anti-
inflammatory drugs, diuretic medication, statin medications, diabetes
and hypertension and accounting for clustering by census tract.

Age, sex, race/ethnicity, hypertension, diabetes and urban/rural status.

Age, sex, BMI, education level, smoking status, alcohol consumption,
hypertension and diabetes.

Age, sex, fasting glucose, cholesterol, hypertension,
BMI, distance to major road, smoking status, alcohol consumption and
education level.

1.97 (1.17 to 3.31)

>19 cigarettes per day
versus no smoking

1.51 (1.06 to 2.15)

>20 cigarettes per day
versus no smoking

1.75 (1.18 to 2.59)

1.24 (0.96 to 1.60)

11–20 cigarettes per day
versus no smoking

1–19 cigarettes per day
versus no smoking

0.89 (0.66 to 2.11)

1–10 cigarettes per day
versus no smoking

1.62 (1.03 to 2.63)

Severe secondhand smoke

1.00 (0.82 to 1.22)

Every 1 µg/m3 increase

1.58 (0.94 to 2.66)

1.05 (1.03 to 1.07)

Quartile 4 versus 1

Moderate secondhand
smoke

1.02 (0.99 to 1.04)
1.01 (0.98 to 1.03)

Quartile 2 versus 1
Quartile 3 versus 1

1.04 (0.94 to 1.15)
1.11 (1.01 to 1.22)

1.05 (0.95 to 1.15)

1.02 (0.97 to 1.07)
1.07 (1.02 to 1.12)

Quartile 2 versus 1

RR (95% CI)

Quartile 3 versus 1

Exposure contrast

Age, sex, educational level, smoking status, alcohol consumption, BMI, Quintile 2 versus 1
systolic BP, fasting glucose, total cholesterol, self-reported heart disease
Quintile 3 versus 1
or stroke and baseline eGFR.
Quintile 4 versus 1

Age, race, sex, cancer, cardiovascular disease, chronic lung disease,
diabetes mellitus,
hyperlipidaemia, hypertension, baseline eGFR, BMI, smoking status,
angiotensin-converting enzyme inhibitor/ angiotensin receptor
blocker use, county population density, number of outpatient eGFR
measurements, number of hospitalisations and county percent in
poverty.

Adjustments

Continued

6

7

9

9

8

9

8

9

8

Risk
of bias
score
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3648

1924

1948

5090

8497

Cross-
sectional

Cross-
sectional

Chen et al
(2018)50

21 656

Weaver et al
(2018)53

Cross-
sectional

Yang et al
(2017)52

100 629

1 164 057

Cohort

Chan et al
(2018)51

2 482 737

Bragg-Gresham Cross-
sectional
et al (2018)1

Cohort

Design

Sample
size

Summary of studies incorporated in integrated non-linear exposure-response modelling

Bowe et al
(2018)2

Reference
(year)

Table 1

BMJ Global Health

1.25 (1.16 to 1.34)

*Incorporated in models when proxy exposures were included.
BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PM2.5, ambient fine particulate matter.

>19 cigarettes/day versus
no smoking in men

1.15 (1.08 to 1.22)
<10 cigarettes/day versus
no smoking in men

10–19 cigarettes/day versus 1.24 (1.16 to 1.32)
no smoking in men

1.43 (1.34 to 1.52)
>19 cigarettes/day versus
no smoking in women

10–19 cigarettes/day versus 1.27 (1.21 to 1.34)
no smoking in women

7
1.30 (1.15 to 1.23)
<10 cigarettes/day versus
no smoking in women

Age, ethnicity, deprivation, smoking, BMI, systolic BP, diabetes,
rheumatoid arthritis, cardiovascular disease, treated hypertension,
congestive cardiac failure, peripheral vascular disease, use of non-
steroidal anti-inflammatory drugs and family history of kidney disease.
systemic lupus erythematosus and kidney stones were additional
adjusted for models in women.

RR (95% CI)
Exposure contrast
Adjustments

eGFR <45 mL/
min/1.73 m2
–
Active
smoking
3 156 494
Cohort

Design

Hippisley-Cox
and Coupland
(2010)*57

Reference
(year)

Exposure
source

Continued
Table 1

Sample
size

Mean or median
exposure range (SD
or IQR)
CKD definition

6

DALYs and death due to CKD attributable to PM2.5 air
pollution are provided in table 2.
In analyses using the exposure–response model where
data from cross-sectional studies were not deweighted,
the burden estimates closely matched those produced
using the primary exposure–response model (where
cross-sectional studies were deweighted), where the estimated absolute number of prevalent cases of CKD and
DALYs due to CKD attributable to PM2.5 were 88.8% and
89.1% of those of the primary model (table 2). In analyses
using the exposure–response model, which also incorporated smoking data produced lower estimates of burden
(table 2), estimating 33.5% and 33.7% as many prevalent cases of CKD and DALYs due to CKD attributable to
PM2.5 as the primary model; when cross-sectional studies
were deweighted, the model estimated 31.5% and 31.8%
as many prevalent cases of CKD and DALYs due to CKD
attributed to PM2.5 as the primary model, respectively.
Burden of CKD attributable to PM2.5 air pollution in 194
countries and territories
We estimated the number, rate per 100 000 persons, and
age-standardised rate per 100 000 persons for incidence,
prevalence, DALYs and death due to CKD attributable to
PM2.5 air pollution for 194 countries and territories based
on the primary model (online supplementary tables
S1–S4). A map of the prevalent number of CKD attributable to PM2.5 is presented in figure 2A. Maps of the
age-standardised DALYs rates, PAF, and age-standardised
incidence, prevalence and death rates due to CKD attributable to PM2.5 air pollution are provided in figure 2B
and online supplementary figures S3–S6, respectively.
Overall, there was substantial geographic variation in
age-
standardised burden, it was more pronounced in
northern Africa, several countries in the Middle East,
Southeast Asia, India and China.
Burden of CKD and sociodemographic development
Age-standardised rates for incidence, prevalence, DALYs
and death due to CKD attributable to PM2.5 pollution by
World Bank income category are provide in table 3. The
results suggest that the burden was higher in low income
and lower middle income countries. Across the development spectrum, there was wide variation in estimated to
expected age-standardised DALY rates where several low
and high SDI countries exhibited substantial deviation
(both higher and lower) from expected burden based on
their level of development (figure 3 and online supplementary table S5).
Burden of CKD attributable to PM2.5 levels above the WHO limit
of 10 µg/m3
We then estimated the burden of CKD attributable to
PM2.5 concentrations above the WHO air quality standards (10 µg/m3). Our results suggest that 72.8% of
prevalent cases of CKD attributable to PM2.5 and 74.2%
of DALYs due to CKD attributable to PM2.5 were due to
concentrations above 10 µg/m3 (table 4).
Bowe B, et al. BMJ Global Health 2020;5:e002063. doi:10.1136/bmjgh-2019-002063
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Discussion
In this work, we integrated all available evidence of the
relationship between PM2.5 and risk of CKD to build and
characterise a non-
linear exposure–response function
to describe the risk of CKD across PM2.5 concentrations
experienced by humans. We estimated that in 2017,
there were 3 284 358.2 (95% UI 2 800 710.5 to 3 747
046.1) incident and 122 409 460.2 (108 142 312.2 to 136
424 137.9) prevalent cases of CKD attributable to PM2.5;
and 6 593 134.6 (5 705 180.4 to 7 479 818.4) DALYs and
211 019.2 (184 292.5 to 236 520.4) deaths due to CKD
attributable to PM2.5 pollution. We produced estimates
of CKD burden attributable to PM2.5 pollution for 194
countries and territories and provided evidence that the
burden is disproportionately borne by low income and
lower middle income countries. Finally, we also show that
72.8% of the prevalent cases of CKD attributable to PM2.5
air pollution and 74.2% of DALYs due to CKD attributable to PM2.5 were associated with PM2.5 levels above the
WHO air quality standards.
We employed four strategies to build the non-linear
exposure-
risk function. We observed that deweighting
cross-
sectional studies did not appreciably influence
the morphology of the risk–exposure model, nor did
it result in substantially different estimates. However,
Bowe B, et al. BMJ Global Health 2020;5:e002063. doi:10.1136/bmjgh-2019-002063

the inclusion of active and passive smoking as proxies
of PM2.5 exposure resulted in a much smaller risk estimates and subsequently much lower burden estimates.
These results are consistent with findings from Burnett
and collaborators18 who noted that prior methodological
approaches that incorporated active and passive smoke
as proxy exposures of PM2.5 resulted in significant underestimation of burden of death attributable to PM2.5 pollution.18 More accurate estimation of CKD burden hinges
on the availability of high-quality cohort studies representing the full spectrum of PM2.5 exposure experienced
by humans.
The WHO now officially recognises air pollution as a
risk factor for non-communicable diseases, and there is
increasing recognition that tackling air pollution is critical to addressing the rising tide of non-communicable
diseases.16 Estimates of burden of non-
communicable
diseases attributable to air pollution are important to
inform this effort, guide policy and inform future directions.12–14 In particular, as experimental evidence has
accumulated over the past decade providing plausible
biological mechanism to explain the effect of PM2.5 on
the kidney,4–10 and as large epidemiological studies
linking PM2.5 exposure with risk of kidney disease and
death due to kidney disease became available, the need
7
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Figure 1 Integrated non-linear exposure–response curve of PM2.5 and CKD. Curves are presented for modelling strategies
where: (A) only PM2.5 study data were used and cross-sectional studies were deweighted; (B) only PM2.5 study data were used;
(C) data from studies on proxy exposure were additionally incorporated and cross-sectional studies were deweighted; and
(D) data from studies on proxy exposure were additionally incorporated. Ninety-five per cent UI are presented as bands. A
reference value of 2.4 µg/m3 was used; all risk under the reference was set to unity. PM2.5, ambient fine particulate matter.
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Modelling strategy
CS studies
deweighted

Proxy
exposures
included

Yes

No

No

Yes

No

No

Yes

Yes

PAF
(95% UI)
19.5
(18.0 to 21.0)

17.4
(15.7 to 19.1)

6.6
(5.1 to 8.2)

6.2
(4.7 to 7.8)

Incidence
(95% UI)

Prevalence
(95% UI)

Number

3 284 358.2
(2 800 710.5 to 3 747
046.1)

122 409 460.2
6 593 134.6
(108 142 312.2 to 136 424 (5 705 180.4 to 7 436
137.9)
870.1)

211 019.2
(184 292.5 to 236 520.4)

Rate (per 100 000)

44.5
(37.9 to 50.7)

1670.3
(1475.9 to 1861.4)

89.9
(77.8 to 101.3)

2.9
(2.5 to 3.2)

Age-standardised rate
(per 100 000)

49.7
(42.7 to 56.4)

1789.6
(1585.0 to 1989.2)

101.6
(87.6 to 115.0)

3.8
(3.2 to 4.3)

Number

2 908 401.2
(2 482 793.5 to 3 378
084.4)

108 679 458.9
(94 881 700.2 to 123 149
917.2)

5 873 622.6 (5 084
600.9 to 6 754 641.3)

187 211.2 (162 460.3 to
213 963.4)

Rate (per 100 000)

39.4
(33.7 to 45.8)

1484.6
(1296.6 to 1682.2)

80.1
(69.4 to 92.1)

2.5
(2.2 to 2.9)

Age-standardised rate
(per 100 000)

44.3
(38.0 to 51.2)

1597.3
(1399.1 to 1806.3)

90.8
(78.2 to 104.7)

3.4
(2.9 to 3.9)

Number

1 089 779.3
(800 761.9 to 1 402
860.4)

41 023 348.8
(30 636 668.8 to 52 184
444.4)

2 223 125.6
(1 652 353.6 to 2 838
639.8)

70 358.4
(52 199.0 to 89 917.9)

Rate (per 100 000)

14.8
(10.9 to 19.1)

561.6
(420.2 to 713.6)

30.4
(22.6 to 38.8)

1.0
(0.7 to 1.2)

Age-standardised rate
(per 100 000)

16.8
(12.5 to 21.5)

607.9
(457.6 to 767.8)

34.6
(25.8 to 44.0)

1.3
(1.0 to 1.6)

Number

1 024 163.8
(744 761.8 to 1 325
643.8)

38 602 132.4
(28 647 072.0 to 49 027
426.1)

2 093 387.4
(1 545 110.3 to 2 673
053.9)

66 159.4
(48 752.8 to 84 245.3)

Rate (per 100 000)

13.9
(10.1 to 18.0)

528.7
(393.1 to 671.3)

28.6
(21.2 to 36.5)

0.9
(0.7 to 1.2)

Age-standardised rate
(per 100 000)

15.9
(11.7 to 20.4)

573.0
(429.2 to 725.6)

32.6
(24.1 to 41.7)

1.2
(0.9 to 1.5)

Measure

DALY
(95% UI)

Death
(95% UI)

Rates are per 100 000 persons
CKD, chronic kidney disease; CS, cross-sectional; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM2.5, ambient fine particulate matter; UI, uncertainty interval.

for a greater understanding and more accurate estimation of the burden of kidney disease attributable to PM2.5
air pollution became more evident.16 58 We previously
provided estimates of CKD burden attributable to PM2.5,
which relied on a single large US cohort study.11 In this
work, we integrated all available evidence and provided
global and national estimates of burden of CKD attributable to PM2.5 air pollution. The GBD study estimates that
exposure to ambient particulate matter pollution is associated with 83 million DALYs59 likely underestimating—
according to Burnett and colleagues18—the global toll of
death and disability attributable to air pollution.18 Our
estimates suggest that CKD DALYs attributable to PM2.5
air pollution were 6.5 million accounting for 7.8% of all
DALYs attributable to ambient particulate matter pollution, reflecting the sizeable toll of this—so far largely
ignored non-communicable disease.12–15 59 As a significant body of epidemiological evidence on the effect of
PM2.5 on risk of kidney disease has accumulated over the
past decade, it is important that PM2.5 and CKD be considered for inclusion as a risk–outcome pair in future iterations of the comparative risk assessment framework of
the GBD study. Such inclusion would allow for the derivation of estimates of the burden of CKD attributable to
ambient PM2.5 air pollution in the same computational
modelling system considering other risks—including
other environmental, occupational, behavioural and
8

metabolic exposures48—and other health outcomes (eg,
under 5 mortality, which may be a competing risk for
non-
communicable diseases manifesting later in life),
thus enabling more accurate comparative estimation
of the burden of diseases attributable to PM2.5 and the
health burden of PM2.5 relative to other risks. The GBD
study framework also facilitates comparative evaluation
of the health sequalae of PM2.5 across geographies and
over time.
We observed that estimates of the burden of CKD attributable to PM2.5 air pollution exhibited substantial geographic
variability and were higher in low and lower middle income
countries—countries that are least equipped to deal with
the untoward health consequences of pollution.11 35 60–62
Variations in PM2.5-associated CKD burden reflect the influence of differences in PM2.5 exposure and differences in
underlying CKD rates. Our estimated to expected ratio
analyses based on SDI suggest that at both ends of the development spectrum there are several countries that exhibited
much higher (and much lower) burden than expected. To
the extent that sociodemographic and economic development may be both a driver for environmental air pollution
and enabler of mitigation mechanisms, the bidirectional
diversion from expected burden across the SDI spectrum
suggests the likely presence of other forces (or drivers)
of this burden and the potential—for so far unrealised—
opportunities for reduction in burden.35 60
Bowe B, et al. BMJ Global Health 2020;5:e002063. doi:10.1136/bmjgh-2019-002063
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Table 2 Estimates of the global burden of CKD attributable to PM2.5 air pollution
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Figure 2 Global burden of CKD attributable to PM2.5 in 194 countries and territories. (A) Prevalence of CKD attributable to
PM2.5; (B) age-standardised disability-adjusted life-years (DALYs) rate (per 100 000) due to CKD attributable to PM2.5. Countries
are coloured by decile. CKD, chronic kidney disease; PM2.5, ambient fine particulate matter. ATG, Antigua and Barbuda; FSM,
Federated States of Micronesia; Isl, Island; LCA, Saint Lucia; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent
and the Grenadines.
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World Bank income
classification

PAF (95% UI)

Incidence (95% UI)

Prevalence (95% UI)

Low income

19.2 (17.6 to 20.8)

66.0 (56.8 to 74.8)

1925.2 (1699.1 to 2147.7) 127.0 (103.5 to 148.8)

4.8 (3.9 to 5.7)

Lower middle income

23.7 (22.0 to 25.5)

68.2 (58.8 to 77.3)

2350.2 (2087.8 to 2605.3) 149.1 (128.8 to 168.7)

5.4 (4.6 to 6.1)

Upper middle income

18.3 (16.8 to 19.8)

34.0 (28.9 to 38.8)

1498.7 (1324.2 to 1669.8)

66.2 (58.4 to 73.9)

2.5 (2.2 to 2.8)

8.9 (8.0 to 9.7)

21.0 (17.6 to 24.1)

643.1 (561.8 to 722.0)

25.6 (21.3 to 29.7)

1.1 (0.9 to 1.3)

High income

DALY (95% UI)

Death (95% UI)

Estimates were generated using the integrated non-linear exposure response model using only PM2.5 data where cross-sectional studies were deweighted.
CKD, chronic kidney disease; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM2.5, ambient fine particulate matter; UI, uncertainty interval.

Our estimates suggest that the majority of the burden
was attributable to PM2.5 levels above the WHO air quality
guidelines for annual mean PM2.5 concentrations. The
findings emphasise that for much of the world PM2.5
levels remain too high and that further effort to reduce
PM2.5 concentrations—and meet the WHO air quality
standards—may be associated with substantial reduction
in burden of CKD worldwide.11 16
This study has several limitations. While we integrated
data from all available studies on PM2.5 and CKD, our
approach is inherently limited by the availability of data,
and in particular, the paucity of large high-quality longitudinal studies of PM2.5 and CKD from areas with very high
PM2.5 concentrations3 and the lack of data for very low
levels of PM2.5 below the TMREL. There was also limited
geographic diversity in the studies of PM2.5 and CKD in
that most were from western countries, few from East Asia,
and none from Africa and the southern hemisphere. Our
analyses did not consider potential heterogeneity of effect
by population or regional characteristics, and we did not
account for potential temporal or geospatial differences
in composition and toxic content of PM2.5. PM2.5 is also
associated with diabetes and hypertension, both known
causal drivers of CKD; while the studies included in our

metaregression analyses considered hypertension and
diabetes as potential confounders, addressing the knowledge gap of whether to what extent the association between
PM2.5 and CKD is mediated by diabetes and hypertension
may help further refine PM2.5 burden attribution. Causal
interpretation should be made with caution. In this work,
we estimated the global and national burden of CKD attributable to PM2.5 using GBD data for CKD burden, and PM2.5
exposure estimates at the national level.63 Our analyses
do not include potential exposure to air pollutants other
than PM2.5 or to indoor air pollutants and do not provide
further insight into PM2.5 attributable burden at the subnational level. Our estimates of CKD attributable to PM2.5 at
the global and national levels reflect the influence of PM2.5
levels across the globe and of demography and underlying
CKD rates.
Strengths include the application of state-
of-
the-
art
methodologies to build an integrated exposure response
function using data from several high-
quality longitudinal cohort studies of PM2.5 and CKD, and in particular,
the incorporation of studies from China where PM2.5
exposure is much higher than western countries. The
functional form of our integrated exposure–response
function and the resulting estimates of burden were not

Figure 3 Map of the estimated to expected ratio of age-standardised disability-adjusted life-years (DALYs) due to CKD
attributable to PM2.5 based on level of sociodemographic development. Countries and territories are coloured by the estimated
to expected ratio the age-standardised DALYs rate based on their sociodemographic index (SDI), where a ratio greater than
one indicates greater than expected age-standardised DALYs, while a ratio less than one is less than expected. CKD, chronic
kidney disease.
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Table 3 Estimates of the population attributable fraction and age-standardised burden rate (per 100 000) of CKD attributable
to PM2.5 by World Bank income classification

BMJ Global Health

Measure

PAF (95% UI)

Incidence (95% UI)

Prevalence (95% UI)

DALY (95% UI)

Death (95% UI)

Number

14.7
(13.6 to 15.8)

2 338 578.5
(2 022 602.3 to 2 673
492.1)

89 111 428.8
(79 647 475.3 to 99 404
342.0)

4 894 988.1
(4 292 855.7 to 5 536
504.6)

152 388.2
(134 514.1 to 171 678.7)

Rate (per 100 000)

32.2 (27.8 to 36.8)

1230.3 (1099.6 to 1372.4) 67.4 (59.2 to 76.3)

2.1 (1.9 to 2.4)

Age-standardised rate (per
100 000)

37.3 (32.5 to 42.5)

1351.6 (1210.7 to 1504.9) 77.5 (67.8 to 87.9)

2.9 (2.5 to 3.3)

Estimates were generated using the integrated non-linear exposure response model using only PM2.5 data where cross-sectional studies were deweighted.
CKD, chronic kidney disease; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM2.5, ambient fine particulate matter; UI, uncertainty interval.

sensitive to deweighting of cross-
sectional studies. To
build our estimates, we leveraged the availability of the
2017 GBD data, which is the most comprehensive compilation and analysis of global health information available,
and provided several measures of burden including incidence, prevalence, DALYs and death.
In sum, we built and characterised an integrated non-
linear exposure–response model for PM2.5 and CKD and
show that the global burden of CKD attributable to PM2.5
air pollution is substantial. The estimated burden was
unevenly distributed, and more disproportionately borne
by low income and lower middle income countries. That
nearly 3/4 of the burden is associated with PM2.5 concentrations above the WHO air quality standards suggests potential unrealised opportunities for reduction in CKD burden.
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